View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 22, 2021

AstraZeneca concludes Alexion acquisition for $39bn

Alexion’s complement-biology platform and pipeline are to be used by AstraZeneca to develop treatments for rare diseases.

AstraZeneca has concluded the acquisition of US-based biopharmaceutical company Alexion Pharmaceuticals for a total consideration of $39bn or $175 per share.

The Alexion shareholders received total consideration of $13.3bn in cash and 236,321,411 new AstraZeneca shares.

With the acquisition, AstraZeneca will enter the rare disease therapies business.

AstraZeneca CEO Pascal Soriot said: “Today we welcome our new colleagues from Alexion to AstraZeneca and begin a new chapter that will augment our growth for years to come.

“Our sustained R&D investment in oncology, cardiovascular and renal, as well as respiratory and immunology, has powered AstraZeneca’s transformation and now we add rare diseases, where fewer approved treatment options exist.”

Alexion develops treatments for immune-mediated rare diseases caused by uncontrolled activation of the complement system, a vital part of the immune system.

Rare diseases signify a growth opportunity with substantial unmet medical needs.

AstraZeneca noted that the company now has an improved scientific presence in immunology.

Leveraging Alexion’s advanced complement-biology platform and pipeline, AstraZeneca will discover and develop treatments for rare diseases.

AstraZeneca chief financial officer and Alexion Pharmaceuticals incoming CEO Marc Dunoyer said: “We look forward to also applying Alexion’s complement-biology platform across areas of AstraZeneca’s broader early-stage pipeline and, significantly, to the extraordinary opportunity to extend existing and future rare disease medicines to patients in many countries where AstraZeneca already has a strong presence.”

The closing of the deal comes after the UK Competition and Markets Authority (CMA) approved the proposed acquisition earlier this month.

In May, the UK CMA launched an investigation into the Alexion acquisition.

The CMA assessed whether the deal would result in a relevant merger situation and if the creation of such a situation will lower competition within any market or in the UK goods or services markets.

The acquisition previously received regulatory clearances in the EU, the US, Japan and other countries worldwide.

Related Companies

Free Report

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy